Founder (Scorpion Therapeutics, Loxo@Lilly, Strata Oncology),
Director Clinical Research - MGH,
Professor - Harvard Med
Keith is a pioneer of therapeutic cancer biomarkers.
He is an accomplished leader in every sphere of this domain: translational medicine, storied academic research, as well as therapeutic and diagnostic industries.
Director GU Oncology & Clinical Trials - AdventHealth Cancer Institute, Director Bladder Cancer - DanaFarber, Professor of Medicine
Guru has published and practiced extensively in the field of clinical oncology at multiple cancer institutes.
He has served as the principal investigator for several clinical trials, currently directs Advent's phase I program, and is extremely cognizant of the latest developments in the cancer therapeutics industry.
Physician Scientist, Medical Oncologist, Genomics Researcher: BWH, Dana-Farber, Broad Institute
Arvind has developed comprehensive expertise across quantitative, experimental, and clinical domains at the highest level of excellence.
This gives him the rare ability to not only see the whole picture but also zoom in wherever necessary.
His foundational research on the role of miRNA in oncogenesis has refined the known biological mechanisms of this omic.
When it comes to the biopharma industry, Alex has seen it all.
Having managed R&D, M&A, and commercial strategy at companies ranging from leading pharmaceuticals, to contract research organizations (CROs) and high-growth technology startups -
his innate ability to navigate challenging situations with precision is unparalleled.